- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04807114
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for Immune Checkpoint Blockade in Non-small Cell Lung Cancer
The main goal of this prospective non-interventional exploratory study is to characterize the tumor micro-environment of advanced NSCLC in single-cell resolution, prior to immune checkpoint blockade exposure, and correlate the findings to clinical outcome. This approach will allow to generate new hypotheses regarding mechanism of action of ICI and (primary) resistance mechanisms. The long-term goal is that these novel mechanistic insights will be translated to a clinical setting to develop better biomarkers of ICI efficacy. Importantly, since the investigators will also sequentially profile the immune composition of peripheral blood, this research offers an opportunity to develop circulating (non-invasive) biomarkers.
A second aim is to characterize the immune cell composition of bronchoalveolar lavage (BAL) fluid from these ICI-treated cancer patients if they would develop ICI-pneumonitis. These mechanistic insights can directly lead to putative diagnostic biomarkers and therpeutic targets. Since single-cell profiling of blood samples will also be performed, circulating biomarkers of ICI toxicity can also be identified, making non-invasive diagnosis feasible.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators will collect tumor biopsies from 70 st.IV NSCLC patients before start of treatment with immune checkpoint inhibitors. These biopsies are taken during a medically required routine procedure for diagnostic purposes, and will be subjected to the following experimental procedures:
First, scRNA-seq and TCR-seq will be applied on up to 5,000 randomly dissociated cells. Additionally, cell surface protein expression can be integrated with the transcriptional information. Various bioinformatics pipelines, including Seurat, will be used to identify different cell clusters, which through marker gene expression will be assigned to known cell types, cellular subtypes or phenotypes. For instance, this will enable the researchers to monitor the abundance of PD-1/PD-L1 expressing T cells, cytotoxic T-cells, immune-suppressive myeloid cells, etc. The following parameters at single-cell level will be relevant (non-exhaustive):
- The composition and relative abundancies of established immune cell types (e.g. T cells (CD4+, CD8+ and regulatory subsets), NK cells, B cells, MDSCs, macrophages, neutrophils, dendritic cells). Transcriptomic data for each of these immune cell subtypes will be analyzed, allowing characterization of specific gene expression programs that define specific phenotypic states.
- Composition of all stromal cellular subtypes identified by single-cell transcriptomics, including fibroblasts and endothelial cells.
- A gene regulatory network for each cell type and cellular subtype (or cell state) will be established and master transcriptional regulators will be identified. Individual T cells and T cell sub-clusters will be classified based on interferon activation, high rates of proliferation and transcription and increased granzyme expression, which are all indicative of T cell activation. Since high CD8+ T cell activity correlates with high immune checkpoint expression, T cell activity (based on granzyme expression) will be correlated with expression of other genes in these cells to identify co-regulated receptors, which possibly represent novel checkpoint molecules.
Blood samples will be subjected to similar experimental procedures. First, PBMC are isolated using Ficoll density gradient centrifugation. Single-cell transcriptome analysis in combination with CITE- seq will be performed on 5000 PBMC. Cellular composition will be determined using the same bioinformatic pipelines as used for processing the tumor biopsies.
As a second objective, immune profiling of the cellular composition of ICI-pneumonitis BAL fluid and PBMC will be performed using scRNA-seq, scTCR-seq and CITE-seq as previously outlined.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Els Wauters
- Phone Number: +3216340942
- Email: els.wauters@uzleuven.be
Study Locations
-
-
-
Leuven, Belgium, 3000
- Recruiting
- Universitaire Ziekenhuizen Leuven
-
Contact:
- Els Wauters, MD, PhD
- Phone Number: +32 16 34 09 42
- Email: els.wauters@uzleuven.be
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- Adult M/F/X (>= 18 years)
- Histologically and clinically confirmed diagnosis of non-small cell lung cancer (according to IASLC Staging Handbook in Thoracic Oncology v7)
- Patients receiving first-line treatment per guidelines
- Not included in other clinical trials
- Signed informed consent form
Exclusion criteria:
• Collected material not suitable for further processing in this study (e.g. bad quality). This decision will be made in consultation with a lab technician and/or bio-informatician, specialized in single-cell analysis.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
NSCLC st.IV (PD-L1 > 50%)
Anti-PD-1 monotherapy
|
Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 > 50%)
Other Names:
|
NSCLC st.IV (PD-L1 < 50%)
Combination anti-PD-1 + chemotherapy
|
Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 < 50%)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune cell proportions, as determined by scRNA-seq, present in tumor samples of ICI-treated st.IV NSCLC patients attaining objective response or not attaining objective response
Time Frame: From date of inclusion until study completion, on average 2 years.
|
By identifying and statistically comparing the percentages of immune cell subtypes present in responding vs. non-responding patients' tumors before start of ICI therapy, we aim to i) understand which immune processes drive response or resistance to ICI ii) identify putative molecular biomarkers iii) identify putative therapeutic targets
|
From date of inclusion until study completion, on average 2 years.
|
Immune cell proportions, as determined by scRNA-seq, present in peripheral blood of ICI-treated st.IV NSCLC patients attaining objective response or not attaining objective response, before and after 1 cycle of ICI
Time Frame: From date of inclusion until study completion, on average 2 years.
|
By identifying and statistically comparing the percentages of immune cell subtypes present in responding vs. non-responding patients' peripheral blood, we aim to i) understand which immune processes drive response or resistance to ICI ii) identify putative molecular biomarkers iii) identify putative therapeutic targets
|
From date of inclusion until study completion, on average 2 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune cell proportions, as determined by scRNA-seq, present in ICI-induced pneumonitis BAL fluid
Time Frame: From date of inclusion until study completion, on average 2 years.
|
By identifying and statistically comparing the percentages of immune cell subtypes present in ICI-/RT-/TKI-induced pneumonitis BAL fluid, we aim to i) understand which immune processes drive these adverse events ii) identify putative molecular biomarkers iii) identify putative therapeutic targets
|
From date of inclusion until study completion, on average 2 years.
|
Immune cell proportions, as determined by scRNA-seq, present in ICI-induced pneumonitis peripheral blood mononuclear cells
Time Frame: From date of inclusion until study completion, on average 2 years.
|
By identifying and statistically comparing the percentages of immune cell subtypes present in ICI-/RT-/TKI-induced pneumonitis peripheral blood mononuclear cells, we aim to i) understand which immune processes drive these adverse events ii) identify putative molecular biomarkers iii) identify putative therapeutic targets
|
From date of inclusion until study completion, on average 2 years.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Els Wauters, MD, PhD, University Hospitals - KU Leuven
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S63531
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Xinqiao Hospital of ChongqingCompleted
-
Seoul St. Mary's HospitalBoehringer IngelheimActive, not recruiting
-
Taipei Veterans General Hospital, TaiwanNational Taiwan University Hospital; China Medical University Hospital; Tri-Service... and other collaboratorsUnknown
-
AstraZenecaCompletedNSCLCSweden, Bulgaria, Mexico, Russian Federation, Turkey, United Kingdom, Philippines, Malaysia, Germany, Hungary, Latvia, Lithuania, Poland, Romania, Netherlands, Norway, Argentina, Australia, Canada, Slovakia, Greece, Taiwan, Thailand, ... and more
Clinical Trials on Immune checkpoint inhibitor
-
Groupe Hospitalier Pitie-SalpetriereInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedAutoimmune Diseases | Endocrine System Diseases | Cancer | Arthritis | Myositis | Neuropathy | Cardiac Disease | OphthalmopathyFrance
-
VastBiomeRecruitingRenal Cell Carcinoma | Non-Small-Cell Lung Carcinoma | Malignant Melanoma | Triple-Negative Breast CancerUnited States
-
Peking University Cancer Hospital & InstituteNot yet recruitingNon Small Cell Lung CancerChina
-
Ospedale Maggiore Di TriesteUnknownHodgkin Lymphoma | Radiotherapy | Immune Checkpoint InhibitorItaly
-
Institut BergoniéInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedCancer Treated With Immune-checkpoint InhibitorsFrance
-
Sun Yat-sen UniversityNot yet recruitingImmune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular CarcinomaChina
-
Groupe Hospitalier Pitie-SalpetriereInstitut CurieCompletedCancer | Immune Checkpoint Inhibitor-Related Myocarditis | Immune-related Adverse EventFrance
-
Hunan Province Tumor HospitalCompletedNon Small Cell Lung CancerChina
-
Peking Union Medical College HospitalNot yet recruitingNon-small Cell Lung CancerChina
-
Hutchison Medipharma LimitedRecruitingExtensive-Stage Small Cell Lung CancerChina